Picture

Questions?

+1-866-353-3335

SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: FirstWord Group | PRODUCT CODE: 1247497

Cover Image

PUBLISHER: FirstWord Group | PRODUCT CODE: 1247497

Systemic Lupus Erythematosus (SLE) -- KOL Insight

PUBLISHED:
PAGES:
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
Multi User License (PDF)
USD 39950

Add to Cart

What clinical factors lead KOLs to welcome the approval of AstraZeneca's Interferon alpha beta receptor antagonist Saphnelo? Why are KOLs enthusiastic about the prospects for Bristol Myers Squibb's pipeline TYK2 inhibitor deucravacitinib? How can industry respond to KOLs' need for effective and less toxic steroid-sparing therapies? KOLs critically assess the prospects of launched and pipeline therapies.

Table of Contents

Executive summary

Treatment algorithm

Research objectives

B-cell activating factor inhibitors

  • Marketed therapies
    • Benlysta (belimumab; AstraZeneca/GlaxoSmithKline)
  • Pipeline therapies
    • Rozibafusp alfa (AstraZeneca)
    • Telitacicept (Yantai Rongchang Pharmaceutical)

Interferon alpha/beta receptor antagonists

  • Marketed therapies
    • Saphnelo (anifrolumab; AstraZeneca)

Regulatory T-lymphocyte stimulants

  • Pipeline therapies
    • Efavaleukin alfa (AMG 592; Amgen)

TYK2 kinase inhibitors

  • Pipeline therapies
    • Sotyktu (deucravacitinib; Bristol Myers Squibb)

Antibody-dependent cell cytotoxicity

  • Pipeline therapies
    • Gazyva/Gazyvaro (obinutuzumab; Roche)

CLEC4C protein inhibitors

  • Pipeline therapies
    • Litifilimab (Biogen)

CD40 ligand inhibitors

  • Pipeline therapies
    • Dapirolizumab pegol (Biogen/UCB)
    • SAR441344 (ImmuNext)

Sphingosine-1-phosphate receptor modulators

  • Pipeline therapies
    • Cenerimod (Idorsia Pharmaceuticals)

Janus kinase 1 inhibitors

  • Pipeline therapies
    • Rinvoq (upadacitinib; AbbVie)

Interleukin-2 replacements

  • Pipeline therapies
    • Rezpegaldesleukin (Eli Lilly and Company)

Dendritic cell inhibitors

  • Pipeline therapies
    • Daxdilimab (Viela Bio)

Fc receptor antagonists

  • Pipeline therapies
    • Nipocalimab (Momenta Pharmaceuticals)

Fc gamma receptor IIA antagonists

  • Pipeline therapies
    • PRV-3279 (Provention Bio)

Future treatment paradigm

  • Key insights summary
    • Effective and less toxic steroid-sparing therapies are the main unmet need identified by KOLs for SLE

Appendix

  • KOL details
    • KOLs from the USA
    • KOLs from Europe

Table of Contents

Executive summary

Treatment algorithm

Research objectives

B-cell activating factor inhibitors

  • Marketed therapies
    • Benlysta (belimumab; AstraZeneca/GlaxoSmithKline)
  • Pipeline therapies
    • Rozibafusp alfa (AstraZeneca)
    • Telitacicept (Yantai Rongchang Pharmaceutical)

Interferon alpha/beta receptor antagonists

  • Marketed therapies
    • Saphnelo (anifrolumab; AstraZeneca)

Regulatory T-lymphocyte stimulants

  • Pipeline therapies
    • Efavaleukin alfa (AMG 592; Amgen)

TYK2 kinase inhibitors

  • Pipeline therapies
    • Sotyktu (deucravacitinib; Bristol Myers Squibb)

Antibody-dependent cell cytotoxicity

  • Pipeline therapies
    • Gazyva/Gazyvaro (obinutuzumab; Roche)

CLEC4C protein inhibitors

  • Pipeline therapies
    • Litifilimab (Biogen)

CD40 ligand inhibitors

  • Pipeline therapies
    • Dapirolizumab pegol (Biogen/UCB)
    • SAR441344 (ImmuNext)

Sphingosine-1-phosphate receptor modulators

  • Pipeline therapies
    • Cenerimod (Idorsia Pharmaceuticals)

Janus kinase 1 inhibitors

  • Pipeline therapies
    • Rinvoq (upadacitinib; AbbVie)

Interleukin-2 replacements

  • Pipeline therapies
    • Rezpegaldesleukin (Eli Lilly and Company)

Dendritic cell inhibitors

  • Pipeline therapies
    • Daxdilimab (Viela Bio)

Fc receptor antagonists

  • Pipeline therapies
    • Nipocalimab (Momenta Pharmaceuticals)

Fc gamma receptor IIA antagonists

  • Pipeline therapies
    • PRV-3279 (Provention Bio)

Future treatment paradigm

  • Key insights summary
    • Effective and less toxic steroid-sparing therapies are the main unmet need identified by KOLs for SLE

Appendix

  • KOL details
    • KOLs from the USA
    • KOLs from Europe
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!